Detailed dose evidence documented for GHRP-2 in its monograph — reference only, not dosing recommendations.
Reference only — not a dosing recommendation.
Approved regimen
Approved labeled regimen
Product-, indication-, and jurisdiction-specific — see the monograph
Japan-approved diagnostic exposure (PMDA): 2 mcg/kg by slow IV injection for ages 4–17 years, capped at 100 mcg; 100 mcg by slow IV injection for adults, administered fasting. A peak GH cutoff of 16 ng/mL is used for children; 9 ng/mL for adults. This is a single-administration diagnostic test for GH deficiency — not a therapeutic regimen and not guidance for self-administration.
Studied in trials
Studied regimens (not recommendations)
Studied in trials — not a recommended dose
No established or recommended human dose. This sentence concerns therapeutic and other unapproved use; it does not erase the separate Japan-specific, single-administration diagnostic label above. Published nontherapeutic pharmacology studies used protocol-specific exposures under research oversight; they do not establish a therapeutic regimen.
Not established
What is not established
Effective therapeutic dose for any non-diagnostic indication
Safety or efficacy of chronic daily administration
Dose finding for body composition or performance claims